Features | Partner Sites | Information | LinkXpress
Sign In

Blood Test Detects Patients at Risk for Diabetes

By Christina Chang, LabMedica Regional Director
Posted on 17 Jul 2012
AACC 2012: A new test being showcased can stratify patients based on risk for developing diabetes.

Even within the healthy range of hemoglobin A1C, the test, dubbed Quantose, detects patients' risk of developing diabetes. It is a novel blood test for prediabetes that reflects insulin resistance. The test is based on three recently identified nonglycemic biomarkers and insulin, and detects progression to prediabetes earlier than traditional glycemic measures such a hemoglobin A1C.

Metabolon (Research Triangle Park, NC, USA) is showcasing the Quantose test, which is a metablomics-driven diagnostic, at the American Association for Clinical Chemistry Lab Expo (AACC) being held from July 15-19, 2012, in Los Angeles (CA, USA). Two posters highlighting the clinical utility of Quantose are being presented at the Expo.

In a poster, the clinical utility of Quantose as a simple, practical measure of insulin resistance will be demonstrated in this poster session with data highlighting the correlations between Quantose and other known risk factors for type 2 diabetes and cardiovascular disease.

In a second poster, differences in insulin resistance using HbA1c and metabolic markers Alpha-hydroxybutyrate, Linoleoyl-GPC, and Oleate are described. This clinical study was performed at the University of North Carolina (Chapel Hill, NC, USA) comparing Quantose metabolic markers to hemoglobin A1C for the ability to detect insulin resistance. Data include the finding that Quantose scores closely track worsening dysglycemia as defined by hemoglobin A1C, but that Quantose also identifies a substantial subset of patients as insulin resistant despite hemoglobin A1C values within the normal range (<5.7%). The clinical study was performed at the University of North Carolina, (Chapel Hill, NC, USA) comparing Quantose metabolic markers to hemoglobin A1C for the ability to detect insulin resistance.

Metabolon, Inc. has developed technology to quickly identify and measure all biochemicals in a biological sample. This method provides a precise understanding of disease etiology and drug action, and advances personalized medicine.

Related Links:

Metabolon
University of North Carolina




ADVANCED INSTRUMENTS
PERIPHERAL VISIONS INC
DiagCor Bioscience
comments powered by Disqus
Life Technologies

Channels

Genetic Tests

view channel
Image: Histopathology of Breast Adenocarcinoma, × 20 magnification (Photo courtesy of Nikon).

Serum Protein Biomarkers Detect Invasive Breast Cancer

The ability of serum protein biomarkers in conjunction with autoantibodies to distinguish between invasive breast cancer and benign breast conditions has been demonstrated. It has been estimated that... Read more

Industry News

view channel

Merck KGaA to Buy Sigma-Aldrich for USD 17 Billion

Merck KGaA (Darmstadt, Germany) will acquire Sigma-Aldrich (St. Louis, MO, USA) for USD 17 billion, expanding its business in North America and gaining exposure in Asia. All outstanding shares of Sigma-Aldrich will be acquired by Merck for USD 140 per share, which would represent a 37% premium to Sigma-Aldrich’s closing... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.